

Remarks

No new matter is added by any of the amendments made herein. Five amendments were made to the specification. One amendment corrects a typographical error in the original application (methyl to methylene). Three amendments provide sequence identifiers for sequences listed in the original specification, including the sequence listing (SEQ ID NOs:199, 200, and 201). One amendment corrects a copying error; Compound No. 158 (the sequence immediately above Compound 159) was copied exactly into the "Name" box for Compound 159. The C-terminal end should have been changed from NH₂ to OH, thereby distinguishing the two compounds. Basis for the correct sequences for Compounds No. 158 and 159 are shown in Examples 141 and 142, respectively, on page 58, lines 5 and 10, of the related Published PCT application PCT/US2004/016625.

Amendments are made herein to correct improper numbering and naming of modifications to sequences in the originally filed sequence listing. The corrected sequences have basis in Table 1 of the specification as originally filed.

Amendments to the claims are also made. Claims 1 and 2 are amended to specifically name MC4R agonist peptides of the present invention. These named peptides are listed as Compound Numbers 2-198 of Table 1 of the original specification. Claims 3-4 and 8-9 are amended to remove the multiple dependence, and new claims 18-21 are added to cover the matter previously claimed through the multiple dependence. Genus claims 5-7 are cancelled. The European style "use" claims 10-17 are cancelled.

No new matter is added by any of the amendments made herein. The Applicants respectfully request that these amendments be fully entered by the Examiner, and that the application be advanced to allowance.

Respectfully submitted,

Paula K. Davis

Paula K. Davis
Attorney for Applicants
Registration No. 47,517
Phone: 317-433-3422

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

4 Aug. 2006

Unmarked Substitute Specification Including Claims

A “clean” version of the substitute specification, including the amended claims and the abstract, is shown on the following pages.